Transcode Therapeutics (RNAZ) Assets Average (2021 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Assets Average came in at $159.8 million in Q1 2026, up 1459.69% YoY from $10.2 million in Q1 2025, and up 90.64% on a QoQ basis from $83.8 million in Q4 2025.
Transcode Therapeutics (RNAZ) Assets Average (2021 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Assets Average data on file, last reported at $159.8 million in Q1 2026.
- Quarterly Assets Average rose 1459.69% year-over-year to $159.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.8 million (up 1459.69% YoY) and the FY2025 annual result came in at $84.8 million, up 1261.44% from the prior year.
- Assets Average improved to $159.8 million in Q1 2026, from $83.8 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $159.8 million in Q1 2026 to a low of $4.4 million in Q3 2024.
- A 5-year average of $22.5 million and a median of $8.1 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average plunged 68.46% — and 2026, when it surged 1459.69%.
- Tracing RNAZ's Assets Average over 5 years: stood at $9.8 million in 2022, then fell by 21.46% to $7.7 million in 2023, then decreased by 27.06% to $5.6 million in 2024, then jumped by 1392.58% to $83.8 million in 2025, then soared by 90.64% to $159.8 million in 2026.
- The last three Assets Average figures came in at $159.8 million (Q1 2026), $83.8 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 154.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159.78 Mn |
| Dec 31, 2025 | 83.81 Mn |
| Sep 30, 2025 | 6.75 Mn |
| Jun 30, 2025 | 10.73 Mn |
| Mar 31, 2025 | 10.24 Mn |
| Dec 31, 2024 | 5.62 Mn |
| Sep 30, 2024 | 4.38 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 7.70 Mn |
| Sep 30, 2023 | 8.05 Mn |
| Jun 30, 2023 | 5.74 Mn |
| Mar 31, 2023 | 6.59 Mn |
| Dec 31, 2022 | 9.80 Mn |
| Sep 30, 2022 | 13.09 Mn |
| Jun 30, 2022 | 16.50 Mn |
| Mar 31, 2022 | 20.89 Mn |
| Dec 31, 2021 | 24.15 Mn |
| Sep 30, 2021 | 13.44 Mn |